Tags

Type your tag names separated by a space and hit enter

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.
BMC Neurol. 2011 Oct 14; 11:125.BN

Abstract

BACKGROUND

Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than clinical measures; however, clinical and MRI outcomes tend to correlate poorly.

METHODS

In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability Status Scale score ≤4.0]) receiving interferon (IFN) β-1a therapy (44 or 22 µg subcutaneously [sc] three times weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In this post hoc analysis, MRI outcomes and correlations between MRI parameters and clinical and functional outcomes were analysed.

RESULTS

MRI data over 3 years were available for 164 patients. T2 lesion and T1 gadolinium-enhancing (Gd+) lesion volumes, but not black hole (BH) volumes, decreased significantly from baseline to Year 3 (P < 0.0001). Percentage decreases (baseline to Year 3) were greater with the 44 μg dose than with the 22 μg dose for T2 lesion volume (-10.2% vs -4.5%, P = 0.025) and T1 BH volumes (-7.8% vs +10.3%, P = 0.002). A decrease in T2 lesion volume over 3 years predicted stable QoL over the same time period. Treatment with IFN β-1a, 44 μg sc tiw, predicted an absence of cognitive impairment at Year 3.

CONCLUSION

Subcutaneous IFN β-1a significantly decreased MRI measures of disease, with a significant benefit shown for the 44 µg over the 22 µg dose; higher-dose treatment also predicted better cognitive outcomes over 3 years.

Authors+Show Affiliations

National Neurological Institute, C Mondino Foundation, Pavia, Italy. stefano.bastianello@yahoo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21999142

Citation

Bastianello, Stefano, et al. "Changes in Magnetic Resonance Imaging Disease Measures Over 3 Years in Mildly Disabled Patients With Relapsing-remitting Multiple Sclerosis Receiving Interferon Β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) Study." BMC Neurology, vol. 11, 2011, p. 125.
Bastianello S, Giugni E, Amato MP, et al. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurol. 2011;11:125.
Bastianello, S., Giugni, E., Amato, M. P., Tola, M. R., Trojano, M., Galletti, S., Luccichenti, G., Quarantelli, M., Picconi, O., & Patti, F. (2011). Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 11, 125. https://doi.org/10.1186/1471-2377-11-125
Bastianello S, et al. Changes in Magnetic Resonance Imaging Disease Measures Over 3 Years in Mildly Disabled Patients With Relapsing-remitting Multiple Sclerosis Receiving Interferon Β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) Study. BMC Neurol. 2011 Oct 14;11:125. PubMed PMID: 21999142.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. AU - Bastianello,Stefano, AU - Giugni,Elisabetta, AU - Amato,Maria Pia, AU - Tola,Maria-Rosalia, AU - Trojano,Maria, AU - Galletti,Stefano, AU - Luccichenti,Giacomo, AU - Quarantelli,Mario, AU - Picconi,Orietta, AU - Patti,Francesco, AU - ,, Y1 - 2011/10/14/ PY - 2011/06/09/received PY - 2011/10/14/accepted PY - 2011/10/18/entrez PY - 2011/10/18/pubmed PY - 2012/1/24/medline SP - 125 EP - 125 JF - BMC neurology JO - BMC Neurol VL - 11 N2 - BACKGROUND: Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than clinical measures; however, clinical and MRI outcomes tend to correlate poorly. METHODS: In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability Status Scale score ≤4.0]) receiving interferon (IFN) β-1a therapy (44 or 22 µg subcutaneously [sc] three times weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In this post hoc analysis, MRI outcomes and correlations between MRI parameters and clinical and functional outcomes were analysed. RESULTS: MRI data over 3 years were available for 164 patients. T2 lesion and T1 gadolinium-enhancing (Gd+) lesion volumes, but not black hole (BH) volumes, decreased significantly from baseline to Year 3 (P < 0.0001). Percentage decreases (baseline to Year 3) were greater with the 44 μg dose than with the 22 μg dose for T2 lesion volume (-10.2% vs -4.5%, P = 0.025) and T1 BH volumes (-7.8% vs +10.3%, P = 0.002). A decrease in T2 lesion volume over 3 years predicted stable QoL over the same time period. Treatment with IFN β-1a, 44 μg sc tiw, predicted an absence of cognitive impairment at Year 3. CONCLUSION: Subcutaneous IFN β-1a significantly decreased MRI measures of disease, with a significant benefit shown for the 44 µg over the 22 µg dose; higher-dose treatment also predicted better cognitive outcomes over 3 years. SN - 1471-2377 UR - https://www.unboundmedicine.com/medline/citation/21999142/Changes_in_magnetic_resonance_imaging_disease_measures_over_3_years_in_mildly_disabled_patients_with_relapsing_remitting_multiple_sclerosis_receiving_interferon_β_1a_in_the_COGnitive_Impairment_in_MUltiple_Sclerosis__COGIMUS__study_ L2 - https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-11-125 DB - PRIME DP - Unbound Medicine ER -